Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2009 2
2012 1
2013 3
2014 1
2015 1
2017 4
2018 4
2019 2
2020 4
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer.
Moyano-Galceran L, Pietilä EA, Turunen SP, Corvigno S, Hjerpe E, Bulanova D, Joneborg U, Alkasalias T, Miki Y, Yashiro M, Chernenko A, Jukonen J, Singh M, Dahlstrand H, Carlson JW, Lehti K. Moyano-Galceran L, et al. Among authors: hjerpe e. EMBO Mol Med. 2020 Apr 7;12(4):e11177. doi: 10.15252/emmm.201911177. Epub 2020 Mar 2. EMBO Mol Med. 2020. PMID: 32115889 Free PMC article.
Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
Dahm-Kähler P, Holmberg E, Holtenman M, Rådestad AF, Borgfeldt C, Hjerpe E, Marcickiewicz J, Bjurberg M, Tholander B, Hellman K, Kjølhede P, Högberg T, Rosenberg P, Åvall-Lundqvist E, Stålberg K. Dahm-Kähler P, et al. Among authors: hjerpe e. Gynecol Oncol. 2021 Apr;161(1):244-250. doi: 10.1016/j.ygyno.2021.01.012. Epub 2021 Feb 10. Gynecol Oncol. 2021. PMID: 33581846
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist).
Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G. Lindemann K, et al. Among authors: hjerpe e. Br J Cancer. 2017 Feb 14;116(4):455-463. doi: 10.1038/bjc.2016.435. Epub 2017 Jan 24. Br J Cancer. 2017. PMID: 28118323 Free PMC article. Clinical Trial.
Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds.
Peuget S, Zhu J, Sanz G, Singh M, Gaetani M, Chen X, Shi Y, Saei AA, Visnes T, Lindström MS, Rihani A, Moyano-Galceran L, Carlson JW, Hjerpe E, Joneborg U, Lehti K, Hartman J, Helleday T, Zubarev R, Selivanova G. Peuget S, et al. Among authors: hjerpe e. Cancer Res. 2020 Apr 1;80(7):1538-1550. doi: 10.1158/0008-5472.CAN-19-2069. Epub 2020 Feb 4. Cancer Res. 2020. PMID: 32019870
Survival in endometrial cancer in relation to minimally invasive surgery or open surgery - a Swedish Gynecologic Cancer Group (SweGCG) study.
Borgfeldt C, Holmberg E, Marcickiewicz J, Stålberg K, Tholander B, Lundqvist EÅ, Flöter-Rådestad A, Bjurberg M, Dahm-Kähler P, Hellman K, Hjerpe E, Kjölhede P, Rosenberg P, Högberg T. Borgfeldt C, et al. Among authors: hjerpe e. BMC Cancer. 2021 Jun 2;21(1):658. doi: 10.1186/s12885-021-08289-3. BMC Cancer. 2021. PMID: 34078319 Free PMC article.
Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study.
Bjurberg M, Holmberg E, Borgfeldt C, Flöter-Rådestad A, Dahm-Kähler P, Hjerpe E, Högberg T, Kjølhede P, Marcickiewicz J, Rosenberg P, Stålberg K, Tholander B, Hellman K, Åvall-Lundqvist E. Bjurberg M, et al. Among authors: hjerpe e. Gynecol Oncol. 2019 Nov;155(2):229-236. doi: 10.1016/j.ygyno.2019.08.022. Epub 2019 Aug 30. Gynecol Oncol. 2019. PMID: 31477283
23 results